Oct 8, 2014
TSX Exchange Symbol: RVX
CALGARY, Oct. 8, 2014 /CNW/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced that, at its annual meeting of shareholders held on October 8, 2014, each of the five nominees proposed as a director and listed in its management information circular dated August 25, 2014 (the "Information Circular") were elected as directors. Proxy voting results for each nominee are set out below:
| Votes For | Votes Withheld | % For | % Withheld | |
| Donald J. McCaffrey | 19,598,577 | 272,713 | (98.63%) | (1.37%) |
| Peter Johann | 19,735,454 | 135,836 | (99.32%) | (0.68%) |
| Kelly McNeill | 19,598,354 | 272,936 | (98.63%) | (1.37%) |
| Kenneth Zuerblis | 19,745,389 | 125,901 | (99.37%) | (0.63%) |
| Eldon Smith | 19,618,789 | 252,501 | (98.73%) | (1.27%) |
About Resverlogix
Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-1. RVX-208 is a first in-class small molecule for the treatment of atherosclerosis and other chronic diseases such as Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information, please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.
| Company Contacts: | |
| Donald J. McCaffrey | Sarah Zapotichny |
| President and CEO | Director, Investor Relations |
| Resverlogix Corp. | Resverlogix Corp. |
| Phone: 403-254-9252 | Phone: 403-254-9252 |
| Email: don@resverlogix.com | Email: sarah@resverlogix.com |
SOURCE Resverlogix Corp.